BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34633954)

  • 1. [Targeted therapies with BRAF inhibitors for pediatric low- and high-grade gliomas with BRAFv600e mutation. Prof. Dr. Juan P. Garrahan Hospital experience].
    Warriner E; Fernández Ponce N; Freytes C; Sampor C; Oller A; Rugilo C; Lubieniecki F; Vazquez V; Alderete D; Baroni LV
    Medicina (B Aires); 2021; 81(5):791-799. PubMed ID: 34633954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma.
    Leclair NK; Lambert W; Roche K; Gillan E; Gell JJ; Lau CC; Wrubel G; Knopf J; Amin S; Anderson M; Martin JE; Bookland MJ; Hersh DS
    Neurosurg Focus; 2022 Dec; 53(6):E15. PubMed ID: 36455272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.
    Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
    Oncotarget; 2017 Jan; 8(1):583-595. PubMed ID: 27611946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of
    Wagner MW; Hainc N; Khalvati F; Namdar K; Figueiredo L; Sheng M; Laughlin S; Shroff MM; Bouffet E; Tabori U; Hawkins C; Yeom KW; Ertl-Wagner BB
    AJNR Am J Neuroradiol; 2021 Apr; 42(4):759-765. PubMed ID: 33574103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF Inhibition in
    Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
    Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
    Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabrafenib and trametinib in BRAFV600E mutated glioma.
    Brown NF; Carter T; Kitchen N; Mulholland P
    CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma.
    Lassaletta A; Guerreiro Stucklin A; Ramaswamy V; Zapotocky M; McKeown T; Hawkins C; Bouffet E; Tabori U
    Pediatr Blood Cancer; 2016 Nov; 63(11):2038-41. PubMed ID: 27398937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib plus trametinib in patients with BRAF
    Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
    Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
    Bautista F; Paci A; Minard-Colin V; Dufour C; Grill J; Lacroix L; Varlet P; Valteau-Couanet D; Geoerger B
    Pediatr Blood Cancer; 2014 Jun; 61(6):1101-3. PubMed ID: 24375920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
    del Bufalo F; Carai A; Figà-Talamanca L; Pettorini B; Mallucci C; Giangaspero F; Antonelli M; Badiali M; Moi L; Bianco G; Cacchione A; Locatelli F; Ferretti E; Mastronuzzi A
    J Transl Med; 2014 Dec; 12():356. PubMed ID: 25524464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF inhibitors in BRAFV600E-mutated pediatric high-grade gliomas: Upfront or at recurrence?
    Nobre L; Bouffet E
    Neuro Oncol; 2022 Nov; 24(11):1976-1977. PubMed ID: 35750023
    [No Abstract]   [Full Text] [Related]  

  • 14. The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.
    Dasgupta T; Haas-Kogan DA
    Front Oncol; 2013; 3():110. PubMed ID: 23717811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained Tumor Control With MAPK Inhibition in
    Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
    Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
    Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
    Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With
    Johanns TM; Ferguson CJ; Grierson PM; Dahiya S; Ansstas G
    J Natl Compr Canc Netw; 2018 Jan; 16(1):4-10. PubMed ID: 29295876
    [No Abstract]   [Full Text] [Related]  

  • 18. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.
    Tan JY; Wijesinghe IVS; Alfarizal Kamarudin MN; Parhar I
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33557011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Dabrafenib for three children with brainstem BRAF
    Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
    J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.